Addressing challenges of cultivated meat
Cultivated meat offers a sustainable option for genuine animal meat, but addressing key challenges through research is essential for its success.
Policy
Were the Impossible and Beyond burgers a fad, or is plant-based meat here to stay?
GFI's Audrey Gyr and Dr. Priera Panescu Scott discuss the opportunities, and challenges, facing the plant-based meat industry.
Make alternative proteins part of your climate story
Alternative proteins are a critical piece of the climate puzzle. Find inspiration for future stories here.
AIM for Climate Summit
The United States will host the AIM for Climate Summit at the JW Marriott on May 8-10, 2023, in Washington, D.C.
The Business of Alt Protein: Navigating FDA’s Pre-Market Food Ingredient Evaluation Programs
Join GFI and the FDA for a seminar on how to navigate the agency's pre-market food ingredient evaluation programs, including the generally recognized as safe (GRAS) Notification Program, and the food and color additive petition programs.
Making Alt Proteins The New Default: Duke & UNC Alt. Proteins Conference
Register for the nation's first student-led alternative proteins conference, hosted by the Duke Alt Protein Project and the Chapel Hill Alt Protein Project on April 14 at Duke University!
FDA gives 2nd safety nod to cultivated meat, produced without slaughtering animals
GFI's Bruce Friedrich celebrates FDA's greenlight of GOOD Meat's cultivated chicken.
GFI celebrates FDA’s second greenlight to a cultivated meat company in a matter of months
GFI experts respond to FDAs “no questions” letter issued to GOOD Meat, marking the first time a cultivated meat product has received regulatory approval on multiple continents.
The Vegan Women Summit
Join the Vegan Women's Summit to connect with leading CEOs, celebrities, investors, and other leaders working to build an animal-free future.
Cultivated meat’s regulatory pathway
The FDA has completed its first safety evaluation for cultivated meat. What comes next? Learn more about cultivated meat’s regulatory path to market.
